TriSalus Life Sciences Inc(TLSI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.29 | Insider Own | 38.12% | Shs Outstand | 61.5M | Perf Week | 3.06% |
| Market Cap | 0.23B | Forward P/E | - | EPS next Y | 20.21% | Insider Trans | 3.19% | Shs Float | 38.1M | Perf Month | -10.84% |
| Enterprise Value | 0.22B | PEG | - | EPS next Q | -0.13 | Inst Own | 35.38% | Short Float | 9.04% | Perf Quarter | -22.11% |
| Income | -0.06B | P/S | 5.05 | EPS this Y | 82.02% | Inst Trans | 2.03% | Short Ratio | 13.23 | Perf Half Y | -15.72% |
| Sales | 0.05B | P/B | 34.72 | EPS next 5Y | - | ROA | -54.38% | Short Interest | 3.44M | Perf YTD | -46.99% |
| Book/sh | 0.11 | P/C | 4.92 | EPS past 3/5Y | 77.5% -140.62% | ROE | - | 52W High | -53.46% ($7.95) | Perf Year | -20.77% |
| Cash/sh | 0.75 | P/FCF | - | Sales past 3/5Y | 53.85% - | ROIC | -69.26% | 52W Low | 68.18% ($2.20) | Perf 3Y | -19.57% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -9.85% | Gross Margin | 85.79% | Volatility(W/M) | 6.56% 5.94% | Perf 5Y | -62.81% |
| Dividend TTM | - | EV/Sales | 4.79 | Sales Y/Y TTM | 25.25% | Oper. Margin | -67.68% | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.97 | EPS Q/Q | 42.4% | Profit Margin | -130.17% | RSI (14) | 38.43 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.35 | Sales Q/Q | 1.73% | SMA20 | -4.74% ($3.88) | Beta | 0.48 | Target Price | $10.4 |
| Payout | - | Debt/Eq | 5.26 | Earnings | 2026/11/10 | SMA50 | -16.53% ($4.43) | Rel Volume | 0.42 | Prev Close | $3.86 |
| Employees | 102 | LT Debt/Eq | 5.22 | EPS/Sales Surpr. | -3.23% 11.1% | SMA200 | -15.97% ($4.4) | Avg Volume(3M) | 0.26M | Price | $3.7 |
| IPO | 2021/2/8 | Option/Short | Yes/Yes | Trades | 1070 | Volume | 108,586 | Change | -4.15% |
🩺 TriSalus Life Sciences (TLSI) is a U.S. medical device company specializing in drug delivery technology for treating solid tumors, including liver cancer. Its core assets include a pressure-based drug delivery platform and the FDA-approved TriNav Infusion System, and the company is expanding its business in the field of interventional oncology, which improves the efficiency with which anti-cancer drugs reach tumors.
Over the past 1 year, roughly in the middle
53% below its 1-year high.
Traded less than usual. That is 42% of its average volume.
Next earnings report: November 10
10 days to go.
TLSI has weak earnings and a weak balance sheet
Of every $100 in sales, $67.68 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +82.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $505. Peers typically go for $143.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -62.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 35.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #75 of 142 in the industry
Based on market cap of $228M.
LAB#73 Standard BioTools Inc $241M PER - 
PROF#74 Profound Medical Corp $240M PER - TLSI#75 TriSalus Life Sciences Inc $228M PER - 
ELMD#76 Electromed Inc $224M PER 20.8 
RXST#77 RxSight Inc $203M PER - 
FAQ
What kind of company is TLSI?
TLSI belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TLSI?
The market cap of TLSI is approximately $228M, ranking 3,906 within its sector.
What is the 52-week high and low for TLSI?
TLSI has recorded a 52-week high of $7.95 and a low of $2.20.
